Tricyclic oxazolidone derivatives useful as PR modulators

Details Tricyclic oxazolidone derivatives useful as PR modulators Tricyclic oxazolidone derivatives useful as PR modulators

2007-08-13

2009-11-17

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S150000

Reexamination Certificate

active

07618989

ABSTRACT:
Compounds of the following structure are described:wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

REFERENCES:
patent: 3320270 (1967-05-01), Rice et al.
patent: 3558662 (1971-01-01), Bruderer et at
patent: 4008243 (1977-02-01), Wikel et al.
patent: 4150028 (1979-04-01), Paget et al.
patent: 4216313 (1980-08-01), Paget et al.
patent: 4268679 (1981-05-01), Lavanish
patent: 4293558 (1981-10-01), Paget et al.
patent: 4426527 (1984-01-01), Lavanish et al.
patent: 4756744 (1988-07-01), Schwindeman
patent: 5698574 (1997-12-01), Riedl et al.
patent: 5719136 (1998-02-01), Chwalisz et al.
patent: 5972372 (1999-10-01), Saleh et al.
patent: 6125850 (2000-10-01), Sokal et al.
patent: 6126958 (2000-10-01), Saleh
patent: 6239152 (2001-05-01), Gordeev et al.
patent: 6436966 (2002-08-01), Ohkawa et al.
patent: 6531470 (2003-03-01), Gordeev et al.
patent: 6620825 (2003-09-01), Ohkawa et al.
patent: 2002/0115669 (2002-08-01), Wiedeman et al.
patent: 2002/0183371 (2002-12-01), Gordeev et al.
patent: 2003/0114491 (2003-06-01), Kim et al.
patent: 2003/0216373 (2003-11-01), Gravestock et al.
patent: 2004/0157883 (2004-08-01), Chen et al.
patent: 2004/0167192 (2004-08-01), Solow-Cordero et al.
patent: 2004/0214870 (2004-10-01), Xin et al.
patent: 0 244 803 (1994-10-01), None
patent: 1127875 (1968-09-01), None
patent: 1224995 (1971-03-01), None
patent: 6703864 (1967-03-01), None
patent: WO 92/07567 (1992-05-01), None
patent: WO 92/09586 (1992-06-01), None
patent: WO 95/15955 (1995-06-01), None
patent: WO 97/36882 (1997-10-01), None
patent: WO 98/00420 (1998-01-01), None
patent: WO 98/04534 (1998-02-01), None
patent: WO 99/42455 (1999-08-01), None
patent: WO 99/64416 (1999-12-01), None
patent: WO 99/64417 (1999-12-01), None
patent: WO 00/01676 (2000-01-01), None
patent: WO 01/70733 (2001-09-01), None
patent: WO 01/74811 (2001-10-01), None
patent: WO 01/80841 (2001-11-01), None
patent: WO 02/50071 (2002-06-01), None
patent: WO 02/081453 (2002-10-01), None
patent: WO 03/011859 (2003-02-01), None
patent: WO 03/027085 (2003-04-01), None
patent: WO 03/101985 (2003-12-01), None
patent: WO 2004/014384 (2004-02-01), None
patent: WO 2004/014899 (2004-02-01), None
patent: WO 2004/019938 (2004-03-01), None
patent: WO 2004/087698 (2004-10-01), None
patent: WO 2004/089303 (2004-10-01), None
patent: WO 2005/005435 (2005-01-01), None
Stella, Valentino J, Expert Opinion of Therapeutic Patents, Prodrugs as therapeutics, 2004 14(3): 277-280.
Wolff et al. (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977, 1994).
Testa, Bernard, Biochemical Pharmacology, Prodrug Research: futile or fertile? 68 (2004) 2097-2106.
Ettmayer, Peter, Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, 47(10) (2004) 2394-2404.
Kwon, Younggil. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. Jun. 24, 2001. p. 213, paragraph 3.
“Metabolomics.” Retrieved online via the Internet [Jun. 24, 2008] URL: www.en.wikipedia.org/wiki/Metabolomics.
“Tautomer.” Retrieved online via the Internet [Jun. 24, 2008] URL: http://en.wikipedia.org/wiki/Tautomer.
Golub et al. Science (1999), vol. 286 521-537.
Lala et al. Cancer and Metastasis Reviews (1998), 17(1), 91-106.
“Cancer.” Retrieved online via the Internet [Jun. 24, 2008] URL: http://www.nlm.nih.gov/medlineplus/cancer.html.
“Uterine Fibroids.” Retrieved online via the Internet [Jun. 24, 2008] URL: http://www.mayoclinic.com/health/uterine-fibroids/DS00078/DSECTION=prevention.
“Endometriosis.” Retrieved online via the Internet [Jun. 24, 2008] URL: http://www.mayoclinic.com/health/endometriosis/DS00289/DSECTION=prevention.
“Polycystic Ovary Syndrome.” Retrieved online via the Internet [Jun. 24, 2008] URL: http://women.webmd.com/tc/polycystic-ovary-syndrome-pcos-prevention.
U.S. Appl. No. 11/891,729, filed Aug. 13, 2007, Commons et al.
U.S. Appl. No. 11/891,727, filed Aug. 13, 2007, Commons et al.
U.S. Appl. No. 11/891,821, filed Aug. 13, 2007, Commons et al.
U.S. Appl. No. 11/891,728, filed Aug. 23, 2007, Commons et al.
U.S. Appl. No. 11/891,748, filed Aug. 13, 2007, Commons et al.
David J. Mangelsdorf, Carl Thummel, Miguel Beato, Peter Herrlich, Günther Schütz, Kazuhiko Umesono, Bruce Blumberg, Philippe Kastner, Manuel Mark, Pierre Chambon and Ronald M. Evans, The nuclear receptor superfamily: The second decade, Cell, vol. 83, Issue 6, Dec. 15, 1995, pp. 835-839.
André Ulmann, Rémi Peyron and Louise Silvestre, Clinical Uses of Mifepristone (MFP), Annals of the New York Academy of Sciences, Jun. 1995—vol. 761 Steroid Receptors and Antihormones, pp. 248-260.
Kekkonen, et al, Fertility and Sterility, 60, 610, 1993.
Horwitz, et al, Horm. Cancer, 283, 1996, pub: Birkhaeuser, Boston, Mass., ed. Vedeckis.
AA Murphy, LM Kettel, AJ Morales, VJ Roberts, and SS Yen, Regression of uterine leiomyomata in response to the antiprogesterone RU 486, J Clin Endocrinol Metab 1993 76: 513-517.
Kettel, et al., Fertility and Sterility, 56, 402, 1991.
Horst Michna, Karsten Parczyk, Martin R. Schneider and Yukishige Nishino, Differentiation Therapy with Progesterone Antagonists Annals of the New York Academy of Sciences, Jun. 1995—vol. 761 Steroid Receptors and Antihormones, pp. 224-247.
B. Testa and J. Caldwell, “Prodrugs Revisited: The “Ad Hoc” Approach as a Complement to Ligand Design”, Medicinal Research Reviews, 16(3):233-241, ed., John Wiley & Sons (1996).

Affiliated with

Also associated with

Rating

Tricyclic oxazolidone derivatives useful as PR modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic oxazolidone derivatives useful as PR modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic oxazolidone derivatives useful as PR modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4088982